CN102164617A - 在受试者体内实现持续的治疗药物浓度的组合物和方法 - Google Patents

在受试者体内实现持续的治疗药物浓度的组合物和方法 Download PDF

Info

Publication number
CN102164617A
CN102164617A CN2009801371326A CN200980137132A CN102164617A CN 102164617 A CN102164617 A CN 102164617A CN 2009801371326 A CN2009801371326 A CN 2009801371326A CN 200980137132 A CN200980137132 A CN 200980137132A CN 102164617 A CN102164617 A CN 102164617A
Authority
CN
China
Prior art keywords
prodrug
days
administration
tumor
enzyme inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801371326A
Other languages
English (en)
Chinese (zh)
Inventor
M·A·伊顿
S·S·哈利特
T·L·贝克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of CN102164617A publication Critical patent/CN102164617A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2009801371326A 2008-09-23 2009-09-23 在受试者体内实现持续的治疗药物浓度的组合物和方法 Pending CN102164617A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US9951608P 2008-09-23 2008-09-23
US61/099,516 2008-09-23
US10693108P 2008-10-20 2008-10-20
US61/106,931 2008-10-20
US17343309P 2009-04-28 2009-04-28
US61/173,433 2009-04-28
PCT/US2009/005284 WO2010036335A1 (en) 2008-09-23 2009-09-23 Compositions and methods for achieving sustained therapeutic drug concentrations in a subject

Publications (1)

Publication Number Publication Date
CN102164617A true CN102164617A (zh) 2011-08-24

Family

ID=41268391

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801371326A Pending CN102164617A (zh) 2008-09-23 2009-09-23 在受试者体内实现持续的治疗药物浓度的组合物和方法

Country Status (21)

Country Link
US (3) US8906353B2 (https=)
EP (1) EP2349346B1 (https=)
JP (3) JP2012503602A (https=)
KR (1) KR20110063457A (https=)
CN (1) CN102164617A (https=)
AU (1) AU2009297091B2 (https=)
CA (1) CA2736939C (https=)
CY (1) CY1122208T1 (https=)
DK (1) DK2349346T3 (https=)
ES (1) ES2744975T3 (https=)
HR (1) HRP20192120T1 (https=)
HU (1) HUE047352T2 (https=)
IL (1) IL211888A (https=)
LT (1) LT2349346T (https=)
MX (1) MX2011003063A (https=)
PL (1) PL2349346T3 (https=)
PT (1) PT2349346T (https=)
RS (1) RS59607B1 (https=)
SI (1) SI2349346T1 (https=)
SM (1) SMT201900609T1 (https=)
WO (1) WO2010036335A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104813167A (zh) * 2012-11-28 2015-07-29 尼克塔治疗公司 用于评估和预测用一种长效拓扑异构酶i抑制剂进行乳腺癌治疗的疗效的方法
CN106539557A (zh) * 2016-10-08 2017-03-29 西安交通大学 一种基于恒速静脉输入的药代动力学参数的测定方法
CN115317486A (zh) * 2022-08-17 2022-11-11 南昌大学 一种共载紫杉醇和伊立替康前药纳米制剂及其制备方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE047352T2 (hu) 2008-09-23 2020-04-28 Nektar Therapeutics Eljárás ütemezett beadásra kamptotecin elõgyógyszerekkel (például PEG-ironotekánnal)
WO2012137225A1 (en) * 2011-04-08 2012-10-11 Sphaera Pharma Pvt. Ltd Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
US20160250177A1 (en) * 2015-02-17 2016-09-01 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof
KR102383824B1 (ko) 2016-06-02 2022-04-06 이노파막스, 인크. 암 치료법을 위한 메트로놈 경구 젬시타빈
JP7546552B2 (ja) 2018-09-17 2024-09-06 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア ポリマーベースの高分子プロドラッグ
CA3209512A1 (en) * 2021-02-23 2022-09-01 Edison Oncology Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1852740A (zh) * 2003-09-17 2006-10-25 阿拉巴马耐科塔医药公司 多支链聚合物的药物前体

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024476A1 (en) 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5614549A (en) 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
TW438775B (en) 1995-04-07 2001-06-07 Pharmacia & Upjohn Co Llc Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
DE69735057T2 (de) 1996-03-12 2006-08-31 PG-TXL Co., L.P., Houston Wasserlösliche paclitaxel-prodrogen
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6111107A (en) 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
EP1176985A2 (en) 1999-04-28 2002-02-06 Vectramed, Inc. Enzymatically activated polymeric drug conjugates
WO2000066125A1 (en) 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
AU781839B2 (en) 1999-12-22 2005-06-16 Nektar Therapeutics Sterically hindered derivatives of water soluble polymers
AU2001257577A1 (en) 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
US6629995B1 (en) 2000-03-31 2003-10-07 Super Gen, Inc. Camptothecin conjugates
EP1301810B1 (en) 2000-07-21 2008-09-10 Services Petroliers Schlumberger Nuclear magnetic resonance methods for extracting information about a fluid in a rock
EP1355671A2 (en) 2000-11-30 2003-10-29 Nektar Therapeutics Al, Corporation Water-soluble polymer conjugates of triazine derivatives
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US7401013B2 (en) 2001-10-15 2008-07-15 Lockheed Martin Corporation Method to optimize test data
WO2003037384A2 (en) 2001-10-29 2003-05-08 Nektar Therapeutics Al, Corporation Polymer conjugates of protein kinase c inhibitors
KR20050042013A (ko) 2001-10-30 2005-05-04 넥타르 테라퓨틱스 에이엘, 코포레이션 레티노산의 수용성 중합체 콘쥬게이트
JP2005517648A (ja) * 2001-12-07 2005-06-16 インターミューン インコーポレイテッド 肝炎ウイルス感染症を治療するための組成物および方法
US6608076B1 (en) 2002-05-16 2003-08-19 Enzon, Inc. Camptothecin derivatives and polymeric conjugates thereof
CN1668293A (zh) 2002-06-06 2005-09-14 华盛顿大学 使用青蒿素样化合物预防或延缓癌症显现的方法
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
BRPI0314042B8 (pt) 2002-09-06 2021-05-25 Calando Pharmaceuticals Inc polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
EP1989212B1 (en) 2006-02-17 2013-06-19 Cascade Prodrug Inc. Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs
WO2008098178A2 (en) * 2007-02-09 2008-08-14 Enzon Pharmaceuticals, Inc. Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
CN101199857B (zh) * 2007-12-12 2011-04-13 中国药科大学 mPEG-PLA-喜树碱类药物的结合物
HUE047352T2 (hu) 2008-09-23 2020-04-28 Nektar Therapeutics Eljárás ütemezett beadásra kamptotecin elõgyógyszerekkel (például PEG-ironotekánnal)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1852740A (zh) * 2003-09-17 2006-10-25 阿拉巴马耐科塔医药公司 多支链聚合物的药物前体

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104813167A (zh) * 2012-11-28 2015-07-29 尼克塔治疗公司 用于评估和预测用一种长效拓扑异构酶i抑制剂进行乳腺癌治疗的疗效的方法
CN104813167B (zh) * 2012-11-28 2019-04-09 尼克塔治疗公司 用于评估和预测用一种长效拓扑异构酶i抑制剂进行乳腺癌治疗的疗效的方法
CN106539557A (zh) * 2016-10-08 2017-03-29 西安交通大学 一种基于恒速静脉输入的药代动力学参数的测定方法
CN115317486A (zh) * 2022-08-17 2022-11-11 南昌大学 一种共载紫杉醇和伊立替康前药纳米制剂及其制备方法
CN115317486B (zh) * 2022-08-17 2024-04-19 南昌大学 一种共载紫杉醇和伊立替康前药纳米制剂及其制备方法

Also Published As

Publication number Publication date
MX2011003063A (es) 2011-04-21
EP2349346B1 (en) 2019-08-28
RS59607B1 (sr) 2020-01-31
KR20110063457A (ko) 2011-06-10
HRP20192120T1 (hr) 2020-02-21
HUE047352T2 (hu) 2020-04-28
US20150087668A1 (en) 2015-03-26
US20180028525A1 (en) 2018-02-01
JP2012503602A (ja) 2012-02-09
ES2744975T3 (es) 2020-02-27
EP2349346A1 (en) 2011-08-03
CY1122208T1 (el) 2020-11-25
IL211888A (en) 2015-08-31
SI2349346T1 (sl) 2019-12-31
US9801873B2 (en) 2017-10-31
PT2349346T (pt) 2019-10-24
CA2736939A1 (en) 2010-04-01
PL2349346T3 (pl) 2020-03-31
US10525051B2 (en) 2020-01-07
AU2009297091A1 (en) 2010-04-01
JP2016216510A (ja) 2016-12-22
SMT201900609T1 (it) 2020-01-14
LT2349346T (lt) 2019-09-25
IL211888A0 (en) 2011-06-30
JP6076317B2 (ja) 2017-02-08
US20110269789A1 (en) 2011-11-03
WO2010036335A1 (en) 2010-04-01
JP2015034180A (ja) 2015-02-19
CA2736939C (en) 2021-09-14
US8906353B2 (en) 2014-12-09
AU2009297091B2 (en) 2015-03-05
DK2349346T3 (da) 2019-10-07

Similar Documents

Publication Publication Date Title
CN102164617A (zh) 在受试者体内实现持续的治疗药物浓度的组合物和方法
Venditto et al. Cancer therapies utilizing the camptothecins: a review of the in vivo literature
US20170266293A1 (en) Methods of treating cancers with therapeutic nanoparticles
EP2515942B1 (en) Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
US20150265716A1 (en) Nanoparticles For Targeted Delivery of Multiple Therapeutic Agents and Methods of Use
JP2018065862A (ja) 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
CN104812381A (zh) 用于制备治疗性纳米颗粒的方法
JP2015187160A (ja) 治療的標的化ナノ粒子の製作に用いるためのジブロックコポリマーで官能化された標的薬の製造方法
TW201936179A (zh) Ｈｓｐ９０－靶定之共軛物及其調配物
Jeetah et al. Polymeric nanomicelles for sustained delivery of anti-cancer drugs
US20230080135A1 (en) Micellar composition from an amphiphilic copolymer for tumor therapy
Abualsoud et al. Advancements in nanotechnology for PARP inhibitor delivery: a comprehensive review of diverse nanosystems, their mechanisms, and therapeutic applications across cancer and beyond
US20250120912A1 (en) Synergistic nanomedicine delivering topoisomerase i toxin (sn-38) and inhibitors of polynucleotide kinase 3'-phosphatase (pnkp) for enhanced treatment of colorectal cancer
HK1155083B (en) Method of metronomic dosing with camptothecin prodrugs (e.g. peg-irinotecan)
HK1155083A (en) Method of metronomic dosing with camptothecin prodrugs (e.g. peg-irinotecan)
Yu et al. Polylactide-tethered SN38 prodrugs in polymeric nanoparticles as reliable nanomedicines for the treatment of cervical cancer
Lee Roles of Passively and Actively Targeted Block Copolymer Micelles in Cancer Therapy
BRPI0915166B1 (pt) nanopartículas compreendendo pla-peg e pla-plga carreadoras de agentes para o tratamento do câncer e seus usos

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110824